Background {#Sec1}
==========

The prognosis for lung cancer is poor, with a 12% average 5-year survival rate in Europe \[[@CR1]\] falling to only 10% in England and Wales \[[@CR1]\]. However, there is considerable clinical heterogeneity between the patients comprising the overall population with lung cancer. If identified early enough, radical treatment including surgery can provide the best chance of a cure. Approximately 80% of lung cancers are non-small cell types, which spread less rapidly than small cell lung cancer, but still have poor prognosis \[[@CR2]\].

A prognostic factor is any measure that is associated with the risk of future health outcomes in those with existing disease \[[@CR3]\], including sociodemographic factors, patient characteristics, health seeking behaviours, health service factors, and clinical characteristics. Genuine prognostic factors can play an important role in pathways towards improved clinical outcomes \[[@CR4]\]. They are crucial in developing treatment plans and providing reliable information on prognosis or survival. However, the potential value of a prognostic factor is dependent on the availability of consistent evidence of its prognostic ability across multiple studies \[[@CR4]\].

Prognostic research aims to understand the course, determinants, or probability of outcome in a cohort. In contrast, prognostic factor research is more specific and aims to identify independent factors that might be useful modifiable targets for interventions to improve outcomes, building blocks for prognostic models, or predictors of differential treatment response \[[@CR4]\]. Prognostic research is summarised as four inter-related research themes in a framework introduced by the PROGnosis RESearch Strategy (PROGRESS) partnership: theme 1, overall prognosis research, investigates the average prognosis or likely course of disease \[[@CR5]\]; theme 2, prognostic factor research, explores the independent impact of individual prognostic factors on lung cancer survival \[[@CR4]\]; theme 3, prognostic model research, aims to develop, validate, or assess the impact of a statistical model which combines multiple factors from which the risk of lung cancer survival can be calculated for individual patients \[[@CR6]\]; and finally, theme 4, stratified medicine research, aims to identify characteristics of patients likely to derive most clinical benefit or least harm from a specific treatment \[[@CR7]\].

We aimed to identify prognostic factors consistently shown to be associated with lung cancer survival in published literature, and determine which factors may be modifiable and could be targeted to improve survival. Systematic reviews provide the gold standard approach for synthesising the evidence as they use standardised and empirically tested methods to minimise bias and error. However, the literature on prognostic factors in lung cancer is increasing exponentially \[[@CR8]\], with hundreds of prognostic factors having already been identified \[[@CR9]\]. A comprehensive, in-depth systematic review of primary studies was not feasible within a reasonable timescale. A rapid review approach was therefore developed based on elements of existing systematic review methodology and accepted practice \[[@CR10], [@CR11]\]. One approach to developing a summary of the existing evidence in a short timeframe is to conduct a systematic review (or overview) of existing reviews \[[@CR12], [@CR13]\]. Overviews of reviews are a relatively new and increasingly popular approach \[[@CR14], [@CR15]\]. Evidence mapping is another new tool that has been developed for addressing the challenges of a large evidence base, and belongs to the family of systematic approaches to reviewing the evidence \[[@CR16], [@CR17]\]. The methods for conducting, interpreting, and reporting overviews of reviews are still in their infancy, and guidance for their conduct is limited \[[@CR15], [@CR18], [@CR19]\]. Guidance is especially limited for the less common types of overview, such as those addressing reviews of prognosis or diagnostic test accuracy \[[@CR15]\]. The methodology for conducting systematic reviews of prognostic research is also still evolving with no accepted guidance on how best to conduct them \[[@CR20]\].

The current review provides an example of the development and application of the combined use of these newly evolving methods for reviewing an extensive body of research evidence, in this instance on prognostic factors to inform decision-making. This paper focuses on the methodological approach used and is intended to inform those with an interest in review methods; it does not provide an in-depth presentation of the findings of prognostic factors associated with lung cancer.

Methods {#Sec2}
=======

Review methods {#Sec3}
--------------

We conducted a pragmatic review of reviews using a three-stage approach, as outlined in Table [1](#Tab1){ref-type="table"}. This included an initial mapping review of the prognostic research (stage 1), an overview of reviews of prognostic factor research (stage 2), followed by a more in-depth evaluation of modifiable factors (stage 3). The overall approach was guided by accepted methodological and reporting standards for systematic reviews \[[@CR10], [@CR11], [@CR21]\]. The mapping review was informed by the methods used by the Evidence for Policy and Practice Information (EPPI) Centre and the overview of reviews by guidance for conducting systematic reviews of prognostic factors \[[@CR22], [@CR23]\].Table 1Summary of the review processStageElements of the review processStage 1: initial systematic mapping review of prognostic researchA descriptive map of prognostic research for lung cancer survival based on the assessment of titles and abstracts only. ● Classification of relevant reviews and meta-analysis according to PROGRESS research themes 1--4, lung cancer type, number and type of prognostic factors investigated, and publication type. ● Identification of all prognostic factors, from which a comprehensive coding scheme was developed. ● Identification of prognostic factors deemed to be potentially modifiable (reviewed by two independent public health and clinical stakeholders).Stage 2: overview of systematic reviews of prognostic factor researchA more in-depth review of a subset of systematic reviews focusing on prognostic factor research (PROGRESS research theme 2) based on the assessment of full text publications. ● Summary of key data from included reviews. ● Coding of reviews according to the prognostic factors they addressed. ● Summary of all prognostic factors investigated by each review, including whether or not they were significantly associated with survival^†^, and the direction of the impact.Stage 3: in-depth evaluation of potentially modifiable factorsA more in-depth evaluation of the results of included reviews reporting modifiable factors. ● Summary of the magnitude of the effect of modifiable prognostic factors (where possible).^†^The term 'significant' denotes statistical significance and refers to the results of either the regression or meta-analyses (pooled analysis) or, where no pooled analysis was undertaken, to more than 50% of studies in narrative syntheses. For reviews that reported both pooled analysis and narrative synthesis, this was based on the results of the pooled analysis. Where significant findings were based on only a single study within a review, this was highlighted.

The review team was supported by public health and clinical stakeholders. The underlying purpose of the study, which was funded by Public Health Wales (PHW), was to inform the development of multivariate modelling of Welsh data proposed by the Welsh Cancer Intelligence and Surveillance Unit (WCISU). The stakeholders, in this instance, were therefore the director of WCISU (DWH) and a Consultant Respiratory Physician (GC). The stepped approach enabled us to provide WCISU with preliminary findings at the end of each stage and obtain ongoing feedback on prognostic factors that were likely to be the most relevant for both the multivariate model development, and policy and clinical decision making. The whole review process was also guided by monthly meetings with the stakeholders.

Search strategy {#Sec4}
---------------

MEDLINE, EMBASE, Cochrane Library, and Web of Science were searched in December 2015 using a strategy based on published prognostic factors search strategies \[[@CR24]\], plus a search filter for systematic reviews and meta-analyses (Appendix A in Additional file [1](#MOESM1){ref-type="media"}) \[[@CR25]\]. Searches were limited to 1990 onwards in order to be clinically and methodologically relevant \[[@CR26], [@CR27]\] but were not limited by language. All bibliographic data retrieved by the searches were imported into Endnote X5 and de-duplicated.

Selecting studies for inclusion {#Sec5}
-------------------------------

The titles and abstracts were screened by two independent reviewers (SN, ZHT, TL, RP), using the criteria outlined in Table [2](#Tab2){ref-type="table"}. Relevant references were coded according to the PROGRESS framework theme (stage 1). Articles published in English that appeared to report systematic reviews of prognostic factor studies (PROGRESS theme 2) were retrieved in full and re-evaluated (RL, MH, ND, SN, MAS, AH) for inclusion in the subsequent overview of reviews (stage 2). Disagreements regarding relevance were resolved by discussion or, if necessary, consulting a third reviewer.Table 2Inclusion criteriaInclusion criteriaExclusion criteria and notesStudy designSystematic reviews or meta-analyses.Editorials or commentaries on included reviews.Meta-analyses not conducted as part of a systematic review were excluded from the overview of reviews (see text below).Target populationPatients with a primary diagnosis of lung cancer reported separately from other cancers.Reviews of mixed cancers were only considered if they included \> 1 lung cancer study, with findings reported separately from other cancers. Studies of prognostic or predicative factors for developing lung cancer, in an otherwise healthy population, were not included.Lung cancer studies not reporting on histological subtypes were excluded for the overview of reviews (see text below).Type of prognostic factors (exposure)Any prognostic or predictive factors relating to the patient, tumour, socioeconomic position, or healthcare provider and system were included. Reviews of single or multiple factors were included.The review did not include studies evaluating the effectiveness of treatments to improve survival. However, predictive factors of treatment outcomes (PROGRESS theme 4 research) were considered for inclusion in the mapping review.Outcome measureOverall or cancer specific survival.--Language and publication typeNo language restrictions were used during the searches and mapping review.Non-English language publications and conference abstracts were not included in the overview of reviews.

### Systematic reviews {#Sec6}

Studies were assessed for eligibility as a systematic review based on the eight essential elements outlined in the Cochrane Handbook \[[@CR11]\] and the UK Centre for Reviews and Dissemination's (CRD's) guidance \[[@CR10]\]. These include the following:i.A clearly framed research questionii.Explicit search criteriaiii.A search of more than one reference databaseiv.Pre-defined eligibility criteria for studiesv.Explicit and reproducible methodologyvi.A systematic presentation of the characteristics of included studiesvii.The assessment for the validity of the findings of the included studiesviii.A narrative or quantitative synthesis of the included evidence.

The initial mapping review was based on titles and abstracts only, and therefore, a pragmatic and more liberal definition of a systematic review was used during this stage. However, for the purpose of the overview of reviews, studies had to meet four of the essential criteria (i, ii, iv, viii) for inclusion. Systematic reviews of prognostic factors may be of inferior quality compared with reviews of clinical effectiveness and are possibly less likely to include critical appraisal of included studies. It was therefore decided to use some of the 'essential' elements (iii, v, vi, vii) as quality, rather than inclusion, criteria. Some studies were retrieved in full during the initial mapping review in order to check eligibility, as the reference details were insufficient to make this judgement. Studies that reported a meta-analysis that was not based on a systematic search of the literature were not included in the second stage of the review.

### Meta-analysis {#Sec7}

Meta-analyses using individual patient data (IPD), where raw data from multiple studies are synthesised, are considered the gold standard for synthesising prognostic factor studies \[[@CR28], [@CR29]\]. However, they must be based on a systematic approach and attempt to include all relevant studies in order to avoid producing biased estimates or erroneous conclusions. Meta-analyses of IPD including only studies from a single research group are unlikely to include all relevant data and were excluded.

### Lung cancer subtypes {#Sec8}

Studies reporting on lung cancer as a whole, without distinguishing histological subtypes, were excluded from the overview of reviews unless they investigated prognostic factors that stakeholders deemed to be important and modifiable. Studies that were included in the initial mapping review and reported on lung cancer as a whole were first checked to see if they investigated prognostic factors deemed to be 'modifiable' (see the 'Coding studies and data extraction' section below). Those that did were then presented to the stakeholders to decide whether they should be included, based on the importance of the modifiable factor.

Coding studies and data extraction {#Sec9}
----------------------------------

As part of the initial mapping review, relevant references were coded according to the underlying research questions investigated (prognostic research theme), whether they aimed to evaluate single or multiple factors and whether they were published in the English language (Appendix B in Additional file [2](#MOESM2){ref-type="media"}). This coding was undertaken, using Microsoft Excel, by one reviewer and checked by a second reviewer (SN, ZHT, TL, RP, RL). The type of lung cancer and prognostic factors investigated were also recorded. These data were then used in an iterative manner to develop a comprehensive list of codes for the prognostic factors and lung cancer types. The initial lists were developed by one reviewer (RL) and checked by a second (RP). Included prognostic factors were grouped using the following categorisation or domain headings:tumour characteristics (histology);clinical characteristics (routinely assessed biological variables);'new' biomarkers (biological factors not used in routine practice);metabolic criteria;patient characteristics;healthcare provider and system; andother.

The data extraction and coding of papers retrieved in full (stage 2) were conducted by one reviewer (MH, ND, SN, MAS, AH, RL), with the first 10--15 checked by a second reviewer (RL, MH). The discrepancies were discussed at a weekly team meeting, and the instructions for coding and data extraction updated accordingly. Because of the complexity of the coding, some additional ongoing checking was conducted whilst developing summary tables of the included reviews and summarising the overall findings. The type of data extracted during stage 2 is provided in the summary tables presented in Additional files [3](#MOESM3){ref-type="media"} and [4](#MOESM4){ref-type="media"} (Appendix C and D), and included the overall aim; the year in which the searches were conducted; type of lung cancer and histological subtypes included; the number and type of prognostic factors investigated; the number of included studies; the sample size range; whether included studies were retrospective, prospective, or a mixture of both; whether multivariate analyses were conducted; the type of synthesis and summary measure used; whether additional analyses were undertaken; results; and author's conclusions. A further, in-depth evaluation was conducted of included reviews of modifiable factors, described below. The data were extracted using Microsoft Access, which allowed the various codes to be selected from.

The list of prognostic factors developed as part of the mapping review was assessed by two independent public health and clinical stakeholders (DWH and GC) to identify those that were deemed to be potentially modifiable.

Quality assessment {#Sec11}
------------------

The quality of included reviews (in stage 2) was assessed using eight essential elements of a systematic review \[[@CR10], [@CR11]\], whilst reviews that investigated modifiable prognostic factors were additionally appraised using A Measurement Tool to Assess Systematic Reviews (AMSTAR) \[[@CR30]\].

Synthesis {#Sec12}
---------

The findings of existing reviews can be utilised within an overview of reviews or integrated into a new review in different ways \[[@CR31]\]. The current review represents a rapid review approach, and as such, we chose not to disaggregate and/or re-analyse the existing review findings. Rather, we used the complete reviews and combined their findings in a narrative synthesis.

The findings of the overview of reviews were summarised and analysed using structured tables, listing all the factors investigated by each review, whether or not they were significantly associated with survival, and the direction of impact. Some systematic reviews included a meta-analysis or meta-regression (pooled analysis), whilst others only presented a narrative synthesis. Prognostic factors that were identified as being 'significantly' associated with survival were those that were shown to be statistically significant in either pooled analysis or by more than 50% of studies in the narrative synthesis. For reviews that reported both pooled analysis and narrative synthesis, this was based on the results of the pooled analysis. Pooled analyses and narrative syntheses were summarised separately. Where significant findings were based on only a single included study within a review, this has been highlighted. The magnitude of effects was only extracted for modifiable factors and presented in separate tables. This included both the summary effect estimate and 95% confidence intervals from both univariate and multivariate analysis, where presented.

Results {#Sec13}
=======

Mapping review {#Sec14}
--------------

Database searches identified 4062 references after de-duplication, of which 398 were eligible for the mapping review. Of these, 264 were retrieved in full, reassessed, and re-themed if appropriate; 207 were subsequently included in the overview of reviews (Fig. [1](#Fig1){ref-type="fig"}). A summary of the studies included in the mapping review, indicating the prognostic factors addressed and the type of lung cancer investigated, is available in the Additional file [2](#MOESM2){ref-type="media"} (Appendix B). The final distribution of included references across the four PROGRESS themes was as follows: theme 1, overall prognosis, *n* = 12; theme 2, prognostic factors, *n* = 299; theme 3, prognostic models, *n* = 20; and theme 4, stratified medicine, *n* = 175 (figures differ from those in the PRISMA diagram because 102 studies covered multiple research questions).Fig. 1PRISMA flow diagram

Overview of reviews of prognostic factor research {#Sec15}
-------------------------------------------------

The findings presented here represent a condensed version of the results to provide an illustration of the quantity, breadth, and type of data provided by the review. More details of the included studies are provided in the additional files.

The overview of reviews included 207 systematic reviews investigating the independent effect of prognostic factors on lung cancer survival (theme 2). Reference details and review characteristics are presented in Additional file [3](#MOESM3){ref-type="media"} (Appendix C) along with the findings of the quality assessment.

Most reviews were recent; 105 (51%) had searches conducted between 2013 and 2015, and only 23 (11%) prior to 2007. Most (146/207, 71%) limited inclusion to patients with non-small cell lung cancer (NSCLC); five (2%) focused on small cell lung cancer (SCLC). Thirty two (15%) included any type of lung cancer, 21 (10%) covered multiple cancer sites including lung, one review limited inclusion to lung squamous cell carcinoma, one to lung adenocarcinoma, and one included multiple primary lung cancers. Most (149, 72%) reviews were from East Asia, 54 (26%) from North America, 33 (16%) from Europe, three from West Asia, and one from Southeast Asia. A complete list of prognostic factors and their association with survival is presented in Additional file [4](#MOESM4){ref-type="media"} (Appendix D) and summarised in brief below. Three reviews aimed to identify *any* prognostic factor associated with survival for NSCLC and as such included over 50 prognostic factors. The findings of these reviews are summarised separately in Additional file [5](#MOESM5){ref-type="media"} (Appendix E).

The most frequently evaluated prognostic factors were 'new' biomarkers; 86 were investigated in 138 reviews, although 47 (55%) were each only evaluated in a single review. Eighteen biomarkers were evaluated by three or more reviews: EGFR (*n* = 11), ERCC1 (*n* = 7), K-RAS (*n* = 5), microRNA-155 (*n* = 5), survivin (*n* = 5), CXCR4 (*n* = 4), E-cadherin (*n* = 4), microRNA-21 (*n* = 4), p53 (*n* = 4), CRP (*n* = 4), COX-2 (*n* = 3), FGFR1 (*n* = 3), HER-2 (*n* = 3), HIF-1alpha (*n* = 3), P16 (*n* = 3), TS (*n* = 3), VEGF-C (*n* = 3). EGFR mutation was not found to be a significant factor in 7/11 reviews; ERCC1 was associated with improved survival in chemotherapy patients, but not for patients receiving surgery alone. Poor survival was associated with the presence, high levels, or overexpression of survivin, K-RAS, p53, microRNA-21, CXCR4, VEGF-C, TS, P16, HIF-1alpha, and HER-2 and with reduced E-cadherin levels.

Twenty-one factors relating to tumour characteristics were investigated in 26 reviews; seven were investigated in three or more reviews: circulating tumour cells (CTCs) (*n* = 3), histology (*n* = 6), lymphovascular invasion (LVI) (*n* = 3), nodal status (*n* = 4), stage (*n* = 6), synchronous metastases (*n* = 3), and visceral pleural invasion (VPI) (*n* = 3). Stage is described in more detail under modifiable factors. The presence of CTCs, positive VPI, and LVI was found to be associated with significantly poorer survival in all reviews evaluating these factors. Adenocarcinoma was associated with significantly better survival than squamous cell or other histological subtypes in four out of five reviews.

Eight reviews evaluated the prognostic value of measuring the metabolic activity of the primary tumour. Volumetric parameters evaluated by fluorodeoxyglucose positron emission tomography, including high values of standardised uptake value (SUV), metabolic tumour volume, and total lesion glycolysis were consistently identified as significant prognostic factors of poor survival in all the reviews.

The survival impact of 11 clinical characteristics or routinely assessed biological variables was evaluated in 12 reviews, but none by more than two reviews. High or normal serum albumin and the presence of skin rash associated with targeted chemotherapy treatment (EGFR tyrosine kinase inhibitors) were evaluated by two reviews; both were found to be associated with significantly better survival.

Nine patient characteristics were investigated in nine reviews, five of them in two or more reviews: age (*n* = 3), gender (*n* = 5), performance status (*n* = 2), pre-treatment quality of life (*n* = 2), and smoking status (*n* = 3). Three out of five reviews identified male gender, and two out of three reviews found advanced age to be significant adverse predictors of survival. The remaining three factors are discussed in more detail under modifiable factors, along with BMI, which was only evaluated by one review.

Five factors categorised as 'healthcare provider and system' were investigated in five reviews: insurance status, multidisciplinary team (MDT) patient management, surgical procedural volume, surgeon specialty, and timeliness of care, all of which are discussed in more detail under modifiable factors.

Three prognostic factors categorised as 'other' were investigated by four reviews; two were only evaluated in a single review. Perioperative blood transfusion due to excessive bleeding, which was evaluated by two reviews, was found to be significantly associated with poor survival.

Review of modifiable factors {#Sec16}
----------------------------

One or both independent clinician and public health stake-holders identified twenty-eight modifiable prognostic factors at the mapping stage, summarised in Additional file [6](#MOESM6){ref-type="media"} (Appendix F). However, one included review reported on body mass index (BMI) and weight loss together so these two factors were subsequently combined. Twenty reviews meeting the criteria for inclusion in the overview of reviews evaluated one or more modifiable factor, but only 15 factors were investigated by these reviews. (The remaining 12 factors are detailed in Additional file [6](#MOESM6){ref-type="media"}.) The included reviews are distinguished in this next section using their unique review identification (ID) number presented in brackets. Three reviews that reported findings for lung cancer as a whole, without distinguishing subtypes, did not meet the inclusion criteria but were included based on the importance and potential usefulness of the prognostic factor they evaluated, namely surgeon specialty and the annual volume of surgical lung resections for cancer (414), the presence of tuberculosis (TB) (5789), and duration of the intervals between presentation and diagnosis or treatment (722).

A description of the reviews that investigated modifiable factors is presented in Table [3](#Tab3){ref-type="table"}. The reviews were fairly recent, with all but one conducted from 2007 onwards. However, five reviews (25%) only searched one reference database, and five (25%) did not include a summary of study characteristics. Only seven (35%) reviews reported conducting a quality assessment of included studies. A quality appraisal of the reviews using the AMSTAR tool is presented in Additional file [7](#MOESM7){ref-type="media"} (Appendix G). Almost half of the reviews (9/20 45%) were poor quality, and only two (10%) were considered to be good quality (studies 494 and 695). Most of reviews did not consider unpublished/grey literature or studies not published in the English language. Most reviews did not include an assessment of the scientific quality of the included studies, and the characteristics of included studies were also poorly presented with known prognostic factors, such as age, sex, performance status, stage, and histology, not generally listed. Half of the reviews included patients with NSCLC, and six (30%) included the broader category of lung cancer, whilst none limited inclusion to just SCLC. Three reviews (15%) covered multiple cancer sites, including lung. The 20 modifiable factors investigated by included reviews are summarised in Table [4](#Tab4){ref-type="table"}. However, as shown in the description of the prognostic factors, they were often analysed as multiple subcategories or histological subgroups with varying thresholds. The total number of prognostic factors investigated ranged from one to 20 for 17 reviews, whilst the remaining three evaluated 'any' prognostic factor associated with survival (Table [3](#Tab3){ref-type="table"}). (These three reviews (182, 843, 1051) are also described in more detail in the Additional file [5](#MOESM5){ref-type="media"}.) Only eight reviews reported pooled analyses, using meta-analysis or meta-regression (Table [3](#Tab3){ref-type="table"}), the results of which are presented in Additional file [8](#MOESM8){ref-type="media"} (Appendix H). The level of statistical heterogeneity between included studies, where investigated, was found to be significant in all but one review (695). The findings of the remaining reviews were based primarily on a descriptive summary of whether the findings were statistically significant or not, or a system of 'vote counting'.Table 3Summary of included reviews that investigated modifiable factorsAuthor, yearREV IDCountrySearch year\*DBRMCHQASynthesisPR themeNo. PFs evaluated\*\*LC typeNo. of studiesSample size rangeIncluded UVA or MVAAboshi, 2014182Japan2012NNYNMR2, 413NSCLC (late)65NSNSAshworth, 2013237UK2012YYPNNarrative1, 2Any (total NS)NSCLC (oligometastatic)49 (23 in analysis of PFs)NS (1064 in analysis of PFs)MVAAshworth, 2014105UK2012YYYNMR1, 2, 320NSCLC (oligometastatic)206--262BothBehera, 20165815US2015YNYNMA22NSCLC (I)19 (11 survival)8--110NSBerghmans, 20118434Belgium2009NNPNNarrative2Any (\> 50)NSCLC (III)3942--2048MVABrundage, 20021051Canada2001NNNNNarrative2Any (169)NSCLC88731--1281MVAButtigliero, 2011494Italy2007YYYYNarrative22mxdC (LC/NSCLC)25 (2 LC)294--447MVACarter, 20145362US2010YPNYNarrative2, 412NSCLC (III--IV)54NSMVAChristopoulos, 20135789Greece2013YYNNNarrative21LC174--56 (NS for 3 studies)NSDeghaidy, 2005923Egypt2004NYNNMA21LC (NSCLC/SCLC)2923--1342NSFlorou, 201451Greece2013YNYNNarrative2, 41mxdC NSCLC (early)/SCLC (limited)20 (13 LC; 4 survival only)66--2258NSMontazeri, 2009703Iran2008YNYNNarrative21mxdC NSCLC/SCLC104 (26 LC)30--651MVANeal, 20158441UK2013YYYYNarrative215mxdC (LC/NSCLC)209 (20 LC)103--566NSOlsson, 2009722US2007YYYYNarrative21LC18NS (2 studies with \> 1000 pts)BothParsons, 2010695UK2008YYYYMA1, 21LC (NSCLC/SCLC)1061--611BothPrades, 20155807Spain2012NYYNNarrative21mxdC LC (LC/NSCLC)51 (3 LC; 1 survival)NSNSSalah, 2012467Jordan2010 (IS)YUYNMR28NSCLC (isolated met)51NS (total 62)BothSlatore, 2010621US2008YPYYNarrative21LC (LC/NSCLC)23 (9 survival)249--693,697Bothvon Meyenfeldt, 2012414Netherlands2011YYPNMR23LC19987--90,088MVAYu, 20155489China2014YUNYMA21NSCLC1021--412Yes\*Where the search dates were not reported, this was based on the latest publication year of included studies (IS)\*\*Three reviews, which evaluated 'any' prognostic factor included a minimum of 50 factors: Ashworth, 2013 (237); Berghmans, 2011 (8434); and Brundage, 2002 (1051)*REV ID* review unique identification number, *DB* searched more than one reference database searched, *No.* number, *RM* used explicit and reproducible methodology used, *CH* a systematic presentation of the characteristics of included studies presented, *QA* assessment for the validity of the findings of the included studies conducted, *ADC* adenocarcinoma, *CTX* chemotherapy, *IS* included studies, *LC* lung cancer, *MA* meta-analysis, *met* metastasis, *MR* meta-regression, *MVA* multivariate analysis, *mxdC* mixed cancer, *NS* not stated, *N* no, *NSCLC* non-small cell lung cancer, *PF* prognostic factor, *PR* prognostic research, *RT* radiotherapy, *SCC* squamous cell carcinoma, *SCLC* small cell lung cancer, *surR* surgical resection, *sync* synchronous, *UVA* univariate analysis, *Y* yesTable 4Modifiable prognostic factors evaluated by included reviewsAuthor, year\*REV IDPatient populationPF codeDescriptionStudy designEvaluable studiesSample size rangeSummary measurePooled analysisNarrative synthesis\*\*\*Patient characteristics Carter, 20145362NSCLC (III--IV)BMILess weight loss or normal BMIRetrospective21NSNS+ in 11 studies;\<\> in 10 studies Berghmans, 20118434NSCLC (III)BMIBody mass indexNSNSNSNS+ in 1 study;\<\> NS Berghmans, 20118434NSCLC (III)Weight lossWeight loss (no further details)NSNSNSNS+ in 5 studies;\<\> NS Brundage, 20021051NSCLC (early)Weight lossNo substantial weight lossNS655--207NS\<\> in 6 studies Aboshi, 2014\*\*182NSCLC (late)PSPercentage of patients in study with ECOG PS1 \< 60 (vs ≥ 60)Prospective1339--1217OR\<\> Berghmans, 20118434NSCLC (III)PSGood performance statusNSNSNSNS+ in 13 studies;\<\> NS Brundage, 20021051NSCLC (early)PSHigh performance statusNS1369--408NS+ in 4 studies;\<\> in 9 studies Carter, 20145362NSCLC (III--IV)PSBetter PS, ECOG 0-1/KPS \< 70 (vs ≥ 2, or vs ≥ 80)Retrospective47NSNS+ in 36 studies;\<\> in 11 studies Berghmans, 20118434NSCLC (III)QoLQuality of life (no further details)NSNSNSNS+ in 1 study;\<\> NS Montazeri, 2009\*\*703mxdC (LC)QoLPre-treatment (baseline) quality of lifeNS2630--651NS+ in 24 studies;\<\> in 2 studies Montazeri, 2009\*\*703mxdC LC (NSCLC)QolPre-treatment (baseline) quality of lifeNS1130--573NS+ in 10 studies;\<\> in 1 study Montazeri, 2009\*\*703mxdC LC (SCLC)QolPre-treatment (baseline) quality of lifeNS170NS\<\> in 1 study Carter, 20145362NSCLC (III--IV)QoLBetter pre-treatment health related QoL/fewer symptomsRetrospective6NSNS+ in 6 studies Berghmans, 20118434NSCLC (III)Smoking statusSmoking (no further details)NSNSNSNS+ in 1 study;\<\> NS Brundage, 20021051NSCLC (early)Smoking statusSmoking habit (no further details)NS2350--593NS+ in 2 studies;\<\> in 21 studies Florou, 2014\*\*51mxdC LC (limited SCLC)Smoking statusNon-smoker---during treatment (vs smoker)Retrospective1215NS+ in 1 study Florou, 2014\*\*51mxdC LC (limited SCLC)Smoking statusEx-smoker---at or after diagnosis (vs current smoker)Prospective1284NS+ in 1 study Florou, 2014\*\*51mxdC LC (early NSCLC)Smoking statusEx-smoker---quit smoking before diagnosis (vs current smoker or never smoked)Prospective1543NS\<\> in 1 study; Florou, 2014\*\*51mxdC LC (early NSCLC/limited SCLC)Smoking statusNever smoked (vs ex- or current smoker)Prospective2284--238NS\<\> in 1 study;+ in 1 study Parsons, 2010695NSCLC (mainly I--IIIA)Smoking statusContinued smoking after diagnosis (vs quit smoking) in NSCLCMixed493--311HR\<\> (unadj);− (adj, *n*=1) Parsons, 2010695SCLC (mainly limited)Smoking statusContinued smoking after diagnosis (vs quit smoking) in SCLCRetrospective270--611HR− Carter, 20145362NSCLC (III--IV)Smoking statusLess/no smoking statusRetrospective9NSNS+ in 6 studies;\<\> in 3 studiesHealthcare provider and system Slatore, 2010\*\*621LCInsurance statusMedicaid (vs private, non-Medicaid, or other funded)NS43702--13,469HR/OR− in 4 studies Slatore, 2010\*\*621LC (NSCLC)Insurance statusCommercial or other insurance (vs private insurance)NS2336--1403HR/OR\<\> in 2 studies Slatore, 2010\*\*621LCInsurance statusMedicaid/Medicare (vs Medicare)NS23094--26,073HR− in 2 studies Slatore, 2010\*\*621LC (NSCLC)Insurance statusMedicaid/Medicare (vs Medicare)NS13,094HR− in 1 study Slatore, 2010\*\*621LCInsurance statusMedicare HMO (vs Medicare Fee for Service)NS110,229HR\<\> in 1 study Prades, 2015\*\*5807mxdC (NSCLC)MDTMDT patient managementProspective1NSSurvival rate+ in 1 study von Meyenfeldt, 2012\*\*414LCProcedural volumeHigh hospital annual volume of surgical resections (vs low volume)---post-operative mortalityNS11 (10 in MR)987--90,088OR++ in 6 studies;\<\> in 5 studies von Meyenfeldt, 2012\*\*414LCProcedural volumeHigh hospital annual volume of surgical resections (vs low volume)---overall survivalNS8 (7 in MR)1097--40,754HR\<\>+ in 5 studies;− in 1 study;\<\> in 2 studies von Meyenfeldt, 2012\*\*414LCProcedural volumeHigh annual surgeon procedural volume (vs low volume)---post-operative mortalityNS24841--24,092HR\<\>+ in 2 studies von Meyenfeldt, 2012\*\*414LCSurgeonSurgeon specialty: general thoracic surgeon (vs general surgeon)---post-operative mortalityNS319,745--86,538HR++ in 1 study;\<\> in 2 studies von Meyenfeldt, 2012\*\*414LCSurgeonSurgeon specialty: general thoracic surgeon (vs general surgeon)---overall survivalNS21097--19,745OR\<\>+ in 1 study;\<\> in 1 studies von Meyenfeldt, 2012\*\*414LCSurgeonSurgeon specialty: cardiothoracic surgeon (vs general surgeon)---post-operative mortalityNS319,745--86,538OR++ in 1 study;\<\> in 2 studies von Meyenfeldt, 2012\*\*414LCSurgeonSurgeon specialty: cardiothoracic surgeon (vs general surgeon)---overall survivalNS21097--19,745HR+ in 1 study;\<\> in 1 studies Olsson 2009722LCTimeliness of careShorter intervals to diagnosis or treatmentMixed15NSNS− in 4 studies;\<\> in 8 studies;+ in 3 studies Neal, 20158441mxdC (LC)Timeliness of careShorter diagnostic interval: time from first seen in primary care to diagnosisMixed4122--378NS\<\> in 3 studies;+ in 1 study Neal, 20158441mxdC (NSCLC)Timeliness of careShorter treatment interval: time from first seen in primary care to treatmentRetrospective2415--495NS\<\> in 1 study;− in 1 study Neal, 20158441mxdC (NSCLC)Timeliness of careShorter patient interval: time from symptom onset to first seen in primaryRetrospective2122--7358NS\<\> in 1 study;− in 1 study Neal, 20158441mxdC (LC)Timeliness of careShorter time from symptom onset to diagnosisRetrospective1NS (total 566)NS+ in 1 study Neal, 20158441mxdC (LC)Timeliness of careShorter time from symptom onset to treatmentRetrospective1NS (total 103)NS\<\> in 1 study Neal, 20158441mxdC (NSCLC)Timeliness of careShorter time from symptom onset to being seen in specialist careRetrospective1NS (total 415)NS\<\> in 1 studyClinical characteristics or routinely assessed biological variables Christopoulos, 2013\*\*5789LCTBActive tuberculosis, TB (vs no TB)Retrospective5NSMedian survival− 1 in study;? in 4 studies (no comparative data) Buttigliero, 2011494mxdC LCVitD levelLow serum vitamin D levelProspective2294--447HR\<\> in 2 studies Ashworth, 2014\*\*105NSCLC (oligometastatic)StageIB (vs IA)Prospective206--262HR\<\> Ashworth, 2014\*\*105NSCLC (oligometastatic)StageIIA (vs IA)Prospective206--262HR\<\> Ashworth, 2014\*\*105NSCLC (oligometastatic)StageIIB (vs IA)Prospective206--262HR− (unadj) Ashworth, 2014\*\*105NSCLC (oligometastatic)StageIIIA (vs IA)Prospective206--262HR− (unadj) Ashworth, 2014\*\*105NSCLC (oligometastatic)StageIIIB (vs IA)Prospective206--262HR− (unadj) Ashworth, 2013\*\*237NSCLC (oligometastatic)StageStage I (vs III or IV)Mixed5NSNS+ in 1 studies;\<\> in 4 studies Aboshi, 2014\*\*182NSCLC (late)StagePercentage of patients in study with stage IV disease \< 80 (vs ≥ 80)Prospective1339--1217OR\<\> Salah, 2012\*\*467NSCLC (solitary met)StageIntra-thoracic stage III (vs stage II or I)Retrospective36NSHR− Deghaidy 2005\*\*923LC (NSCLC)StageStage I vs II (in NSCLC)Mixed1023--226RR++ in 5 studies;\<\> in 5 studies Deghaidy 2005\*\*923LC (SCLC)StageStage I vs II (in SCLC)Mixed424--295RR++ in 3 studies;\<\> in 1 study Deghaidy 2005\*\*923LC (NSCLC)StageStage I vs III (in NSCLC)Mixed733--1342RR++ in 4 studies;\<\> in 3 studies Deghaidy 2005\*\*923LC (SCLC)StageStage I vs III (in SCLC)Mixed327--92RR++ in 2 studies;\<\> in 1 study Deghaidy 2005\*\*923LC (NSCLC)StageStage II vs III (in NSCLC)Mixed757--961RR++ in 3 studies;\<\> in 4 studies Deghaidy 2005\*\*923LC (SCLC)StageStage II vs III (in SCLC)Mixed325--95RR+\<\> in 3 studies Deghaidy 2005\*\*923LC (NSCLC)StageStage III vs IV (in NSCLC)Mixed621--2198RR++ in 3 studies;\<\> in 3 studies Deghaidy 2005\*\*923LC (SCLC)StageStage III vs IV (in SCLC)Mixed222--319RR\<\>\<\> in 2 studies Carter, 20145362NSCLC (III--IV)StageLess advanced stage, mainly IIIB (vs IV)Retrospective37NSNS+ in 21 studies;\<\> in 16 studies Behera, 2016\*\*5815NSCLC (I)StageAdenocarcinoma in situ, AIS (vs minimally invasive adenocarcinoma, MIA)NS118--110Survival rate\<\> Berghmans, 20118434NSCLC (III)StageLess advanced stageNSNSNSNS+ in 6 studies;\<\> NS Brundage, 20021051NSCLC (early)StageLess advanced stageNS10331--593NS+ in 68 studies;\<\> in 35 studies Berghmans, 20118434NSCLC (III)T volumeTumour volumeNSNSNSNS+ in 2 studies;\<\> NS Yu, 2015\*\*5489NSCLC (unresectable)GTVSmall gross tumour volume, GTV \< 112 cm3vs (vs large GTV \>= 112cm3)NS532--115HR+Prognostic factors classified as 'other' Ashworth, 2014105NSCLC (oligometastatic)Surgical treatmentSurgical primary LC treatment (vs non-surgical)Prospective206--262HR+ (unadj) Ashworth, 2013237NSCLC (oligometastatic)SurgeryType of thoracic resection: lobectomy (vs pneumonectomy)Mixed2NSNS+ in 1 studies;\<\> in 1 studies Berghmans, 20118434NSCLC (III)SurgeryR0 (complete resection)NSNSNSNS+ in 4 studies;\<\> NS Brundage, 20021051NSCLC (early)SurgerySurgical procedure (no further details)NS1543--593NS+ in 4 studies;\<\> in 11 studies\*Three reviews which evaluated 'any' prognostic factor included a minimum of 50 factors: Ashworth, 2013 (237); Berghmans, 2011 (8434); and Brundage, 2002 (1051). Beghmans, 2011, (which included 39 studies) provided a list of factors found to be significant in multivariate analysis, but did not indicate the number of studies that had evaluated each factor; the description of each factor was also minimal. For Berghmans, 2011 (8434), only factors found to be significant by included studies (reporting multivariate analysis) were listed with minimal descriptors; the total number of studies which evaluated each factor was not reported. Brundage, 2002 (1051), included separate analysis for studies that investigated prognostic factors in resected NSCLC. The description of the prognostic factors were minimal and are reported verbatim here (not stated what the comparator was)\*\*The actual results for these studies are presented in Additional file [8](#MOESM8){ref-type="media"} (Appendix H)\*\*\*Narrative synthesis reported by the review*REV ID* review unique identification number, *BMI* body mass index, *GTV* gross tumour volume, *HR* hazard ratio, *LC* lung cancer, *MR*-meta regression, *MDT* multidisciplinary team, *mxdC* mixed cancer, *NS* not stated, *NSCLC* non-small cell lung cancer, *OR* odds ratio, *PS* performance status, *RR* relative risk, *SCLC* small cell lung cancer, *TB* tuberculosis, *vs* versus

### Patient characteristics {#Sec17}

Four patient-related modifiable factors were investigated: BMI, performance status (PS), quality of life (QoL), and smoking status. These were evaluated in seven reviews, five of which reported a narrative synthesis, one a meta-analysis, and one a regression-analysis. Two of the reviews (1051, 8434) reporting narrative syntheses aimed to evaluate any prognostic factor associated with survival and therefore included both a large number of factors and studies (Tabl [3](#Tab3){ref-type="table"}). One of these reviews (8434) only reported the total number of included studies that identified these factors as significant in their multivariate analysis, without providing the denominators.

Less weight loss or normal BMI at diagnosis was found to be associated with significantly better survival in advanced NSCLC, according to 11/21 studies in one review (5632) and 6 studies in another (which did not report the denominators) (8434). Four reviews investigated the effect of PS (by various measures of wellbeing and activities of daily life) in advanced or metastatic NSCLC. Better PS was found to be significantly associated with survival in 36/47 studies in one review (5362) and 13 in another (8434), whilst it was only found to be a significant factor in 4/13 studies in a third review (1051). The final review did not find it to be a significant influencing factor associated with survival extension, but this analysis was based on first-line chemotherapy trials where the majority of patients had a good PS (182). Three reviews evaluated pre-treatment health-related QoL. Two reviews found that better QoL or fewer symptoms were significantly associated with increased survival in patients with late stage NSCLC, according to all six included studies (5362) or one study (8434). The third review was both poorly conducted and reported, but also found that pre-treatment (baseline) global quality of life scores or some aspects of quality of life measures were significant independent predictors of survival in 24/26 lung cancer studies (703).

Five reviews, including one good quality review (695), evaluated the effect of smoking status. Two reviews showed that quitting smoking at or after diagnosis was associated with better survival than continued smoking in limited SCLC or early NSCLC, but these findings were only significant in SCLC (695, 51). Not smoking was also found to be associated with significantly better survival than smoking in three reviews (8434, 5362, 51), whilst a fourth only reported significant findings in 2/23 studies (1051). One review reported significant findings associated with 'less/no smoking status' and the outcome of advanced NSCLC in multivariate analysis of 6/9 studies (5362); the other reported better survival in patients with limited SCLC who did not smoke during chemo-radiotherapy treatment in one study, although another study reported that neither smoking status at time of diagnosis nor pack years smoked had a significant impact on survival for limited SCLC (8434); a third study found that smoking status both before and after surgery was significantly associated with survival in early NSCLC (51).

### Healthcare provider and system {#Sec18}

Six modifiable factors that were categorised as healthcare provider and system were included: insurance status, multidisciplinary team (MDT) patient management, surgeon, procedural volume, and timeliness of care. These were investigated in five reviews, most of which used a narrative synthesis.

One review from the USA investigated the association between insurance status and survival in patients with NSCLC (621). Patients with Medicaid or no insurance had worse survival, higher incidence rates, and later stage at diagnosis than those with private or Medicare insurance, and were also less likely to undergo curative procedures than those with private, Medicare, or other funded insurance in 6/9 studies.

One review investigated the impact of MDTs on patient outcomes (5807). This was a poor quality systematic review that considered any cancer type. Patient care being managed by an MDT was identified as a significant factor associated with improved survival in NSCLC, according to a single study.

Two reviews evaluated the association between time to diagnosis or treatment, and survival. Both reviews presented a narrative synthesis based on vote counting. The patient journey from symptom onset to diagnosis or treatment initiation can be broken down into multiple different intervals \[[@CR32]\]. One review (722) that investigated the effects of timeliness of care for lung cancer as a whole did not differentiate between the diagnostic and treatment interval, whilst the second review (8441), which evaluated any cancer type, but reported separate data for NSCLC, did distinguish between interval types (outlined in Table [4](#Tab4){ref-type="table"}). In the review limited to lung cancer, shorter intervals were associated with significantly improved survival in three out of eighteen studies, and reduced survival in four; eight studies did not report significant findings (722). The second review reported that shorter intervals between either symptom onset or being seen in primary care, and diagnosis were associated with improved survival in NSCLC, according to a single study (in 1/1 and 1/4 studies, respectively) (8441). However, shorter intervals between symptom onset and first being seen in primary care, and being seen in primary care and starting treatment, were associated with reduced survival, according to one out of 2 studies. The discordant finings reported by both these reviews are likely to be due to the 'waiting time paradox' \[[@CR33]--[@CR35]\], where patients with rapidly growing or metastatic tumours are more likely to experience symptoms that draw attention to the underlying cancer, but have poor outcomes.

One review evaluated the effect of both surgeon specialty and volume of lung resections for cancer in a hospital or by a surgeon on post-operative mortality or overall survival (414). Hospitals performing a high-volume of resections for lung cancer had significantly better outcomes, in terms of post-operative mortality, than low-volume hospitals, but there was no significant difference between the two for overall survival. Surgeon procedural volume showed no significant effect on post-operative mortality, but general surgeons had significantly higher mortality risks than general thoracic or cardiothoracic surgeons.

### Clinical characteristics or routinely assessed biological variables {#Sec19}

Two factors categorised as clinical or routinely assessed biological variables were included: tuberculosis (TB) and serum vitamin D level. Each factor was only evaluated by a single review using a narrative synthesis. According to a very poorly conducted and reported review, the median survival in patients with active TB was 4 months compared with 8 months in patients without TB in one study (5789). Low serum vitamin D was not found to be associated with survival in NSCLC, according to both relevant studies in one good quality review (494).

### Tumour characteristics {#Sec20}

Nine reviews evaluated stage, and two investigated tumour volume as prognostic factors for survival. Three reviews evaluated stage along with other factors in regression analyses. In one review, the regression analyses were undertaken using IPD obtained from the authors of the primary studies (105), and in another, IPD were extracted from the published studies (467).

Tumour stage was identified as a significant factor associated with overall survival on univariate, but not multivariate analysis in two of the reviews (105, 467), and not a significant factor in the multivariate regression analysis undertaken within the third review (182). A further review conducted a series of eight meta-analyses comparing stages I versus II, I versus III, II versus III, and III versus IV, in both NSCLC and SCLC. There was a significant reduction in the relative risk of death for earlier staged tumours when compared with later stages in six meta-analyses (923). One review evaluated the prognostic differences between adenocarcinoma in situ and minimally invasive adenocarcinoma using a meta-analysis, and found no significant differences in survival rates between the two groups (5815). The remaining four reviews included a narrative synthesis. Three found that less advanced stage (mainly IIIB) was associated with significantly better survival than stage IV in the majority of included studies in three reviews (29, 8434, 1051), whilst the fourth found that stage I oligometastatic NSCLC was associated with significant better survival than stage III--IV in 1/5 studies (237). One review investigated the association between gross tumour volume and the prognosis of patients with unresectable NSCLC after radiotherapy treatment. The overall survival was significantly less in patients with a large (≥ 112 cm^3^), compared to small (\< 112 cm^3^), gross tumour volume (5489). A second review noted that tumour volume was identified as a significant factor for stage III NSCLC in two studies of multivariate analysis (8434).

Discussion {#Sec21}
==========

This paper provides an example of the development and application of a pragmatic and innovative approach for reviewing an extensive and complicated body of research evidence to inform decision-making. The review aimed to identify prognostic factors associated with lung cancer survival. It focused on the findings of modifiable factors, but also provided an overview of the evidence relating to any prognostic factor, as well as a useful resource of all the reviews and meta-analyses of broader prognostic research questions. This was achieved using a three-staged reviewing approach, which included an initial mapping review of lung cancer prognostic research, based on titles and abstracts, followed by an overview of systematic reviews evaluating factors that independently contribute to lung cancer survival. A compressive *prognostic factor* coding scheme was developed as part of the mapping review, from which a list of modifiable factors was drawn, based on input from key stakeholders. The overview of reviews, which was based on full text papers, aimed to provide a description of the available reviews and their overall findings. It provided both a summary of the prognostic factors found to be associated with survival and a means of identifying the better quality and more recent reviews. It also allowed us to assess whether there was consistency between the overall findings of multiple reviews assessing the same prognostic factors. The quality of included reviews was assessed using the eight essential criteria for a systematic review \[[@CR10], [@CR11]\]. A more in-depth evaluation was conducted of reviews that considered one or more modifiable factors. This included further data extraction including the magnitude of the effect and quality appraisal using the AMSTAR checklist \[[@CR30]\].

The reviewing approach was successful in providing a systematic and transparent description of the nature and coverage of an exceptionally broad prognostic research field relating to lung cancer survival. It included an overview of more than 80 individual prognostic factors associated with survival, with a special focus on 15 modifiable prognostic factors, such as critical patient characteristics relevant to public health interventions and healthcare provider characteristics relevant for organisational and systemic healthcare redesign.

A well-conducted systematic review provides an essential evidence resource for informing decision-making. However, as highlighted by Ioannidis et al. and identified by our own review, there is a massive production of unnecessary, misleading, and conflicted systematic reviews \[[@CR36]\]. A frequent problem faced by decision-makers is the difficulty in interpreting the findings of multiple reviews reporting inconsistent results and conclusions \[[@CR21], [@CR37]\]. A well-conducted overview of reviews provides an objective assessment of whether the conclusions of individual reviews are consistent or not, as well highlighting the most relevant and high quality reviews. The identification of consistent findings across multiple high-quality systematic reviews also provides more confidence in the value of a prognostic factor. The current reviewing approach was developed with this in mind.

Systematic mapping reviews and overview of reviews can be viewed as rapid review approaches. The combined stepped approach has far ranging applications for present and future healthcare policy priorities with a complicated epidemiology (e.g. other cancers and chronic or degenerative conditions), where a review of wide-ranging systematic reviews is needed in a relatively short timeframe. Systematic mapping reviews are generally used to structure a broad research area, whilst systematic reviews tend to focus on gathering evidence to answer a more focused research question. Both aim to identify and summarise the evidence base in an objective, repeatable, and transparent way. Where there is a broad evidence base, prioritising evidence from systematic reviews limits unnecessary duplication, minimises resources needed to screen and summarise primary level evidence, and reduces potential bias and/or error, which could be incurred by reviewing primary evidence rapidly \[[@CR38]\]. The advantage of using a staged approach is that it provides a valuable description of the available research. The inclusive nature of the mapping review enabled us to identify both individual prognostic factors and reviews that evaluated prognostic factors of specific interest, which would have been excluded from a more focused review. The staged approach also enabled us to reconsider reviews that evaluated prognostic factors deemed to be important and modifiable by the stakeholders, but did not meet the inclusion criteria for the overview of reviews, in a transparent and objective way.

The initial mapping review (stage 1) and the overview of reviews (stages 2--3) represent two consecutively funded studies, each with a 9-month duration (1July 2015--31 March 2016 and 1 July 2016--31 March 2017). The breadth and volume of the evidence base meant that a conventional systematic review of primary studies was not feasible within the overall timeframe. Furthermore, although the primary focus was to identify individual candidate prognostic factors (in prognostic factor research), these are sometimes investigated within, or alongside, other prognostic research studies. Our staged reviewing approach, utilising existing reviews, enabled us to complete both studies on time, whilst maintaining the necessary breadth of the evidence review. However, completing the entire review over 18 months still proved very challenging. This was compounded by the fact that the review was conducted by multiple reviewers working part-time, most of whom worked only on the mapping review (stage 1) or overview of reviews (stage 2--3). In order to maintain consistency, there were weekly team meetings, but on occasion, individual reviewers had to suspend work until queries could be addressed at the next meeting, or re-check work to ensure it was correct. The volume of relevant systematic reviews was far more than expected, and the fact that most of these were fairly recent and poor quality meant that the time available for a more in-depth review of modifying factors (stage 3) was limited. The diversity and complexity of the evidence base also made the review work challenging and time consuming. The main challenge here, as well as the large number of reviews, was that existing reviews varied in terms of the methods used for searching and synthesising the evidence. Furthermore, the primary studies within each review also varied in terms of sample size, population and lung cancer types, methods used to identify prognostic factors, the way in which the factors were measured (as a continuous or binary measure), the thresholds used to categorise the prognostic factors, and the type of variables that were adjusted for in the analysis. In order to expedite the review, we increased the number of reviewers working on it. This also brought its challenges, as it required everyone to implement the complicated inclusion criteria and coding schemes, with much checking required to achieve consistency.

The rapid review approach was based on a narrative synthesis and utilised the overall findings and conclusions of the included reviews \[[@CR31]\]. The magnitude of effect of prognostic factors was only considered for the modifiable factors. However, the findings of most reviews were based on either the statistical significance of included studies or 'vote counting', neither of which is capable of accurately evaluating the association with survival. A review of reviews generally relies on the appraisal and data extraction of previous reviews rather than going back to the primary sources \[[@CR31]\]. Alternatively, existing reviews can be used as a reference source for identifying or selecting primary studies \[[@CR31]\]. A potential next stage of the rapid review approach presented here could include utilising the results of the searches, or data extraction, from a specified subset of included systematic reviews to inform a new synthesis of primary studies. This would enable a more in-depth evaluation of and ensure that any new pooled analysis is not biased by double counting of included studies, which could occur in a meta-analysis of meta-analyses \[[@CR39]\].

In capturing the breadth of the literature, we inevitably lost depth and detail. Limiting inclusion to systematic reviews means some modifiable factors investigated by primary studies but not covered by a systematic review may have been missed. No findings were reported for 12/27 (44%) of the potentially modifiable factors identified from the mapping review. Potential modifiable factors may have been evaluated as part of a non-prognostic factor research question, published as a non-English language publication or conference abstract, or not deemed to be a systematic review. Some studies retrieved in full were found, on inspection, not to meet the inclusion criteria.

The challenge of defining modifiable factors was a potential limitation of our review. The decision on what constitutes a modifiable factor is fairly subjective, and in order to avoid excluding any potentially important modifiable factors, we chose to consider all those identified by either stakeholder. However, it could be argued that the list should have been limited to those that are modifiable once cancer has been diagnosed, thus excluding features of extensive disease which could, in theory, be modified but are unlikely to change patient outcomes. The list used in our review was based on limited input from only two clinicians. A more robust approach would have utilised expert consensus methodology, for example, using a Delphi survey; however, this was not feasible within the confines of the current project. Another potential limitation of our review is the timing of the searches, which were conducted at the end of 2015. However, our report was sufficient to meet the needs of our stakeholders, and since we present the review here as a methodological example, we did not update the searches.

An important limitation of the included reviews, and the available evidence base for the prognostic factors to inform clinical practice, was the limited data presented on histological subtypes. Many reviews focused on the evolution of lung cancer as a whole and only reported limited data on specific subtypes. Notably, three important and potentially useful modifiable factors were only considered by systematic reviews that evaluated lung cancer as a whole. Lung cancer is a heterogeneous disease, with different cell types growing and spreading differently. The feasibility of having any impact on the prognosis of lung cancer is dependent on tumour growth rate and spread of the disease, and as such, research studies lumping lung cancer types can be non-informative for implementation in clinical practice. Even lumping all NSCLC subtypes in one group can be non-informative as shown in systematic review of the natural history and growth rates of NSCLC, which found that the data regarding the distribution of tumour volume doubling time showed a wide spectrum of growth rates \[[@CR40]\]. However, we also acknowledge that the broad remit of our review and the large number of included reviews meant that we have also reported data according to the broader categories of lung cancer types. Better reporting of the findings relating to histological subtypes is required, within both systematic reviews and primary studies.

Our review shows the large volume of systematic reviews that have already been conducted, indicating the need for an overview of current reviews, before yet another systematic review of primary studies is considered. Our review also shows that despite the enthusiasm for conducting systematic reviews of prognostic factors for lung cancer, very few focus on modifiable factors. A recent comprehensive analysis of global lung cancer research conducted over a decade (2004--2013) found that commitment to lung cancer research has fallen in most countries apart from China, and shows that it has no correlation with lung cancer burden \[[@CR41]\]. Our findings corroborate this in that most of the reviews we identified were from China, yet interestingly, only one of these reviews evaluated a potentially modifiable factor (gross tumour volume), which could be argued to be a feature of extensive disease rather than a modifiable factor. Our review also highlights the limitations, in both volume and quality, of the primary studies evaluating modifiable factors.

The review identifies important gaps in the evidence base and potential areas for future, more in-depth, focused systematic reviews. Most of the included reviews focused on prognostic factors for NSCLC, and more reviews are likely to be needed for prognostic factors relating to SCLC. However, better reporting of histological subtypes in primary studies is required, in order to assist subsequent inclusion in future reviews. Further research is also needed to define modifiable factors. Future systematic reviews are likely needed for the 15 potentially modifiable factors for which no findings are reported in the current review.

Conclusions {#Sec22}
===========

The study provides an example of the successful development and application of a novel approach to review the extensive and complicated research on prognostic factors to inform decision-making. It enabled us to develop a summary of the evidence base that is directly relevant to the stakeholders in an objective, repeatable, and transparent way. It also provides essential information for future research. However, it also required extensive planning, management, and ongoing reviewer training, which was time-consuming.

The review identified a large volume of published systematic reviews and meta-analyses of prognostic and predictive factors for lung cancer survival. These provide evidence for a long list of prognostic factors, but interestingly, few were evaluated by multiple reviews. Where multiple reviews did evaluate the same prognostic factors, their findings, on the whole, were fairly consistent. The review identified several potentially modifiable factors for lung cancer survival, which could contribute to evidence-based initiatives to improve lung cancer survival.
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